ClinicalTrials.gg
Drug

SEP-363856 clinical trials

Also written SEP-363856 and Ulotaront.

studies test it
30
open now
4
in phase 3
14
first study started
2013

How each study uses SEP-363856 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the SEP-363856 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

SEP-363856 75mg
2

Development codes

SEP-363856
26

Other names

Ulotaront
3

Studies by the year they started

30 studies that test it; most in 2022 (6)

Studies that test SEP-363856, by start year
YearStudies
20131
20142
20162
20172
20195
20202
20212
20226
20233
20252
20263

By phase

A phase 1/2 study counts in both.

Phase 1
12
Phase 2
6
Phase 3
14

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 30 · Other 0

Otsuka Pharmaceutical Development & Commercialization, Inc. (25) · Sumitomo Pharma Co., Ltd. (4) · Otsuka Pharmaceutical Co., Ltd. (1)

Studies

Open first, then newest update. How each study uses SEP-363856 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 30

See all 30 studies that test SEP-363856 →

As the comparator · 1 — what is tested is compared with SEP-363856

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call SEP-363856 · ClinicalTrials.gg INT001284

  • MeSH (NLM) C000705647SEP-363856One source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.